Literature DB >> 7070886

Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months.

D I Bernstein, J M Zahradnik, C J DeAngelis, J D Cherry.   

Abstract

The reactogenicity and immunogenicity of whole-virus and split-product influenza vaccines were studied in 77 children between the ages of 6 and 36 months. Subjects initially received monovalent vaccine containing either A/USSR/77 (H1N1) antigen in 1978 or A/Brazil/78 (H1N1) antigen in 1979. One month later a trivalent preparation was given which contained the respective H1N1 antigen plus A/Texas/77 (H3N2) and B/Hong Kong/72 antigens. Temperatures of greater than or equal to 37.8 C (greater than or equal to 100 F) were observed more commonly after initial vaccination with whole-virus vaccine (35%) than after split-product vaccine (14%). No child had a temperature of greater than or equal to 39.4 C (103 F) or a febrile convulsion. The trivalent vaccines were more reactogenic than the monovalent vaccines although none of the reaction indices exceeded 0.9. The whole-virus vaccine appeared to be more immunogenic, especially in those children who were initially seronegative (preimmunization hemagglutination-inhibiting antibody titer (less than 5). Only 50% of children vaccinated with split-product vaccines with initial hemagglutination-inhibiting titers of less than 5 achieved titers of greater than or equal to 20 to the H1N1 antigen after two doses of vaccine compared with 97% in similar whole-virus vaccine recipients. The degree of antibody response to the A/Texas/77 component of the vaccines was greater than the response to the A/Brazil/78 or A/USSR/77 antigens.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7070886

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  16 in total

1.  Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial.

Authors:  Mbayame Niang; Meagan E Deming; Deborah Goudiaby; Ousmane M Diop; Ndongo Dia; Aldiouma Diallo; Justin R Ortiz; Doudou Diop; Kristen D C Lewis; Kathryn E Lafond; Marc-Alain Widdowson; John C Victor; Kathleen M Neuzil
Journal:  Vaccine       Date:  2020-10-02       Impact factor: 3.641

2.  Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.

Authors:  Alaina J Mooney; Zhuo Li; Jon D Gabbard; Biao He; S Mark Tompkins
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

3.  Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.

Authors:  Natasha B Halasa; Michael A Gerber; Andrea A Berry; Edwin L Anderson; Patricia Winokur; Harry Keyserling; Allison Ross Eckard; Heather Hill; Mark C Wolff; Monica M McNeal; Kathryn M Edwards; David I Bernstein
Journal:  J Pediatric Infect Dis Soc       Date:  2014-06-27       Impact factor: 3.164

4.  Safety and immunogenicity of trivalent inactivated influenza vaccine in infants.

Authors:  Natasha B Halasa; Michael A Gerber; Qingxia Chen; Peter F Wright; Kathryn M Edwards
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

5.  Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine.

Authors:  Chompoonuch Sawaengsak; Yasuko Mori; Koichi Yamanishi; Ampol Mitrevej; Nuttanan Sinchaipanid
Journal:  AAPS PharmSciTech       Date:  2013-12-17       Impact factor: 3.246

6.  Antibody dynamics of 2009 influenza A (H1N1) virus in infected patients and vaccinated people in China.

Authors:  Ming Wang; Jun Yuan; Tiegang Li; Yang Liu; Jibin Wu; Biao Di; Xi Chen; Xinhong Xu; Enjie Lu; Kuibiao Li; Yanhui Liu; Yejian Wu; Xiongfei Chen; Peng He; Yulin Wang; Jianhua Liu
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

7.  Innate responses induced by whole inactivated virus or subunit influenza vaccines in cultured dendritic cells correlate with immune responses in vivo.

Authors:  Maaike Stoel; Judith Pool; Jacqueline de Vries-Idema; Fatiha Zaaraoui-Boutahar; Maarten Bijl; Arno C Andeweg; Jan Wilschut; Anke Huckriede
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

8.  Investigation into alternative testing methodologies for characterization of influenza virus vaccine.

Authors:  Tracy Tay; Catherine Agius; Ross Hamilton; Jesse Bodle; Steve Rockman
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 9.  Selecting and Using the Appropriate Influenza Vaccine for Each Individual.

Authors:  Toshiki Sekiya; Marumi Ohno; Naoki Nomura; Chimuka Handabile; Masashi Shingai; David C Jackson; Lorena E Brown; Hiroshi Kida
Journal:  Viruses       Date:  2021-05-24       Impact factor: 5.048

10.  Special Edition: Editorial

Authors:  Alan W Hampson; John Wood
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.